Healios (TYO:4593) will seek conditional approval in Japan for MultiStem to treat acute respiratory distress syndrome, following successful Phase 2 studies in Japan, the US, and the UK, according to its filing on Wednesday.
This decision eliminates the need for a planned Phase 3 trial in Japan, originally intended as a confirmatory study.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。